» Articles » PMID: 34541758

FRAX Assessment in People Ageing with HIV

Overview
Journal HIV Med
Publisher Wiley
Date 2021 Sep 20
PMID 34541758
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Current British HIV Association (BHIVA) guidelines recommend the use of FRAX for the routine assessment of bone fracture risk in people living with HIV over 50 years of age every 3 years. Bone mineral density measurement with dual-energy X-ray absorptiometry (DXA) scan is recommended for those with increased fracture risk (FRAX major > 10%). Our objectives were to estimate the prevalence of and risk factors for osteoporosis in a population of PLWH aged > 50 years and assess the utility of FRAX in predicting the presence of DXA-proven osteoporosis in this cohort.

Methods: This was a cross-sectional study of a cohort of PLWH aged > 50 years attending the Chelsea and Westminster Hospital and who had a DXA scan between January 2009 and December 2018. FRAX scores were calculated using the Sheffield algorithm. Multiple regression models and Cohen's kappa values were used to assess risk factors for osteoporosis and agreement between FRAX and DXA scan results, respectively.

Results: In all, 744 patients were included (92.9% male, mean age 56 ± 5 years). The prevalence rates of osteoporosis (at DXA scans) and osteopenia were 12.2% and 63.7%, respectively. FRAX major was > 10% in only two patients, while 90/91 (98.9%) patients with osteoporosis had a normal FRAX score. The presence of osteoporosis was significantly associated with low body mass index and estimated glomerular filtration rate (p < 0.05).

Conclusion: Our results indicate that FRAX scores did not predict the presence of osteoporosis in our population of PLWH over 50 years of age and therefore FRAX scores may not be the appropriate tool to define eligibility to perform DXA scans in PLWH.

Citing Articles

Bone Loss and Fractures in Post-Menopausal Women Living with HIV: A Narrative Review.

Jamshaid M, Heidari A, Hassan A, Mital D, Pearce O, Panourgia M Pathogens. 2024; 13(9).

PMID: 39339002 PMC: 11435029. DOI: 10.3390/pathogens13090811.


Bone Disease in HIV: Need for Early Diagnosis and Prevention.

Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K Life (Basel). 2024; 14(4).

PMID: 38672792 PMC: 11051575. DOI: 10.3390/life14040522.


Living with HIV and Getting Vaccinated: A Narrative Review.

De Vito A, Colpani A, Trunfio M, Fiore V, Moi G, Fois M Vaccines (Basel). 2023; 11(5).

PMID: 37243000 PMC: 10220625. DOI: 10.3390/vaccines11050896.


Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews.

Taiwo B, Romdhani H, Lafeuille M, Bhojwani R, Milbers K, Donga P J Drug Assess. 2022; 12(1):1-11.

PMID: 36582675 PMC: 9793945. DOI: 10.1080/21556660.2022.2149963.


Menopause care in women living with HIV in the UK - A review.

Dragovic B, Rymer J, Nwokolo N J Virus Erad. 2022; 8(1):100064.

PMID: 35242357 PMC: 8866072. DOI: 10.1016/j.jve.2022.100064.